<DOC>
	<DOCNO>NCT00224354</DOCNO>
	<brief_summary>In laboratory , put special gene cancer cell take subject . This gene make cell produce interleukin 2 ( IL-2 ) , may help patient 's immune system kill cancer cell . Also , use CD40 ligand ( CD40L ) IL-2 . Studies cancer animal cancer cell grown laboratory suggest add CD40L help IL-2 work well . Some new cell give back subject vaccine shot . We believe part subject 's immune system ( cell call T-reg cell ) might try kill special cell . If T-reg cell , vaccine would work well last long . To try avoid , special cell put back subject 's body , give intravenous ( IV ) dose IL-2 immunotoxin ( call denileuk diftitox ONTAK ) . ONTAK get rid T-reg cell subject 's body help special cell work well longer . The purpose study learn safety cancer-fighting effect use IL-2 vaccine .</brief_summary>
	<brief_title>Lymphocytic B-Leukemia ( B-CLL ) w/Human IL-2 Gene Modified &amp; Human CD40 Ligand-Expressing Autologous Tumor Cells</brief_title>
	<detailed_description>This phase I trial ass safety deplete regulatory T ( Treg ) cell use 1-3 dos interleukin-2 immunotoxin direct CD25 antigen ( denileukin diftitox , ONTAK ) chronic lymphocytic leukemia ( B-CLL ) patient , follow six subcutaneous ( SC ) injection autologous leukemic cell modify ex vivo secrete human interleukin-2 ( hIL-2 ) express human CD40 ligand ( hCD40L ) . Patients receive fix dose ( 2 x 10e7 ) IL-2 secrete B-cells together 2 x 10e7 hCD40L express B-cells , represent safe , well tolerate immunogenic dose previous dose escalation study . All eligible patient treat six injection . Any patient whose disease regress administration 6 injection may offer injection tumor vaccine sufficient vaccine available . There use placebo control subject .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<criteria>Pre Inclusion Eligibility Criteria : Proof BCLL diagnosis Richter 's transformation Eligibility Criteria : Manipulated BCLL cell available ( least 6 injection ) BCLL measurable disease , Richter 's transformation Life expectancy great equal 10 week ECOG 02 ( see Section 4.3 full protocol detail ) Recovered toxic effect prior chemotherapy Absolute neutrophil count ( ANC ) great equal 500/mL Absolute lymphocyte count ( ALC ) great equal 200/mL Hemoglobin great equal 8 g/dL Platelet count great equal 50,000/mL Total bilirubin less equal 1.5mg/dL SGOT less equal 2 x Normal Normal PTT Creatinine le 3 x Normal ( agerelated ) Creatinine clearance &gt; 80mg/min/1.73m2 Serum albumin level great equal 3 g/dl Must receive treatment investigational agent within last 4 week Practicing appropriate birth control study 3 month study conclude . Congestive heart failure Significant arrythmia history myocardial infarction Active CNS disease history seizure Active infection / receive antibiotic ( prophylactic trimethoprim sulfamethoxazole Seropositive HIV Pregnancy lactation / use birth control method Autoimmune disease ( GvHD , immune thrombocytopeniaITP autoimmune hemolytic anemiaAIHA ) Receiving immunosuppressive drug Hypersensitivity denileukin diftitox component : diphteria toxin , interleukin2 , excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>LYMPHOCYTIC</keyword>
	<keyword>B-LEUKEMIA</keyword>
	<keyword>B-CLL</keyword>
</DOC>